471 results on '"Marlton P."'
Search Results
2. How comparable are patient outcomes in the 'real-world' with populations studied in pivotal AML trials?
- Author
-
Ing Soo Tiong, Meaghan Wall, Ashish Bajel, Akash Kalro, Shaun Fleming, Andrew W. Roberts, Nisha Thiagarajah, Chong Chyn Chua, Maya Latimer, David Yeung, Paula Marlton, Amanda Johnston, Anoop Enjeti, Chun Yew Fong, Gavin Cull, Stephen Larsen, Glen Kennedy, Anthony Schwarer, David Kipp, Sundra Ramanathan, Emma Verner, Campbell Tiley, Edward Morris, Uwe Hahn, John Moore, John Taper, Duncan Purtill, Pauline Warburton, William Stevenson, Nicholas Murphy, Peter Tan, Ashanka Beligaswatte, Howard Mutsando, Mark Hertzberg, Jake Shortt, Ferenc Szabo, Karin Dunne, Andrew H. Wei, and Australasian Leukaemia and Lymphoma Group (ALLG)
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Despite an increasing desire to use historical cohorts as “synthetic” controls for new drug evaluation, limited data exist regarding the comparability of real-world outcomes to those in clinical trials. Governmental cancer data often lacks details on treatment, response, and molecular characterization of disease sub-groups. The Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (ALLG NBCR) includes source information on morphology, cytogenetics, flow cytometry, and molecular features linked to treatment received (including transplantation), response to treatment, relapse, and survival outcome. Using data from 942 AML patients enrolled between 2012–2018, we assessed age and disease-matched control and interventional populations from published randomized trials that led to the registration of midostaurin, gemtuzumab ozogamicin, CPX-351, oral azacitidine, and venetoclax. Our analyses highlight important differences in real-world outcomes compared to clinical trial populations, including variations in anthracycline type, cytarabine intensity and scheduling during consolidation, and the frequency of allogeneic hematopoietic cell transplantation in first remission. Although real-world outcomes were comparable to some published studies, notable differences were apparent in others. If historical datasets were used to assess the impact of novel therapies, this work underscores the need to assess diverse datasets to enable geographic differences in treatment outcomes to be accounted for.
- Published
- 2024
- Full Text
- View/download PDF
3. The effect of salt anion in ether‐based electrolyte for electrochemical performance of sodium‐ion batteries: A case study of hard carbon
- Author
-
Jiabao Li, Jingjing Hao, Quan Yuan, Ruoxing Wang, Frederick Marlton, Tianyi Wang, Chengyin Wang, Xin Guo, and Guoxiu Wang
- Subjects
ether‐based electrolyte ,reaction kinetics ,salt anion ,SEI components ,sodium storage ,Production of electric energy or power. Powerplants. Central stations ,TK1001-1841 - Abstract
Abstract Compared with the extensively used ester‐based electrolyte, the hard carbon (HC) electrode is more compatible with the ether‐based counterpart in sodium‐ion batteries, which can lead to improved cycling stability and robust rate capability. However, the impact of salt anion on the electrochemical performance of HC electrodes has yet to be fully understood. In this study, the anionic chemistry in regulating the stability of electrolytes and the performance of sodium‐ion batteries have been systematically investigated. This work shows discrepancies in the reductive stability of the anionic group, redox kinetics, and component/structure of solid electrolyte interface (SEI) with different salts (NaBF4, NaPF6, and NaSO3CF3) in the typical ether solvent (diglyme). Particularly, the density functional theory calculation manifests the preferred decomposition of PF6− due to the reduced reductive stability of anions in the solvation structure, thus leading to the formation of NaF‐rich SEI. Further investigation on redox kinetics reveals that the NaPF6/diglyme can induce the fast ionic diffusion dynamic and low charge transfer barrier for HC electrode, thus resulting in superior sodium storage performance in terms of rate capability and cycling life, which outperforms those of NaBF4/diglyme and NaSO3CF3/diglyme. Importantly, this work offers valuable insights for optimizing the electrochemical behaviors of electrode materials by regulating the anionic group in the electrolyte.
- Published
- 2024
- Full Text
- View/download PDF
4. Surface and structure engineering of MXenes for rechargeable batteries beyond lithium
- Author
-
Zefu Huang, Majid Farahmandjou, Frederick Marlton, Xin Guo, Hong Gao, Bing Sun, and Guoxiu Wang
- Subjects
MXenes ,Energy storage materials ,2D materials ,Surface engineering ,Structure engineering ,Materials of engineering and construction. Mechanics of materials ,TA401-492 - Abstract
With the rapid growth in renewable energy, researchers worldwide are trying to expand energy storage technologies. The development of beyond-lithium battery technologies has accelerated in recent years, amid concerns regarding the sustainability of battery materials. However, the absence of suitable high-performance materials has hampered the development of the next-generation battery systems. MXenes, a family of 2D transition metal carbides and/or nitrides, have drawn significant attention recently for electrochemical energy storage, owing to their unique physical and chemical properties. The extraordinary electronic conductivity, compositional diversity, expandable crystal structure, superior hydrophilicity, and rich surface chemistries make MXenes promising materials for electrode and other components in rechargeable batteries. This report especially focuses on the recent MXene applications as novel electrode materials and functional separator modifiers in rechargeable batteries beyond lithium. In particular, we highlight the recent advances of surface and structure engineering strategies for improving the electrochemical performance of the MXene-based materials, including surface termination modifications, heteroatom doping strategies, surface coating, interlayer space changes, nanostructure engineering, and heterostructures and secondary materials engineering. Finally, perspectives for building future sustainable rechargeable batteries with MXenes and MXene-based composite materials are presented based upon material design and a fundamental understanding of the reaction mechanisms.
- Published
- 2024
- Full Text
- View/download PDF
5. Shear-induced electrical changes in the base of thin layer-cloud
- Author
-
Harrison, R Giles, Marlton, Graeme, Aplin, Karen L, and Nicoll, Keri
- Subjects
Physics - Atmospheric and Oceanic Physics - Abstract
Charging of upper and lower horizontal boundaries of extensive layer clouds results from current flow in the global electric circuit. Layer-cloud charge accumulation has previously been considered a solely electrostatic phenomenon, but it does not occur in isolation from meteorological processes, which can transport charge. Thin layer clouds provide special circumstances for investigating this dynamical charge transport, as disruption at the cloud-top may reach the cloud base, observable from the surface. Here, a thin (~300 m) persistent layer-cloud with base at 300 m and strong wind shear at cloud-top was observed to generate strongly correlated fluctuations in cloud base height, optical thickness and surface electric Potential Gradient (PG) beneath. PG changes are identified to precede the cloud base fluctuations by 2 minutes, consistent with shear-induced cloud-top electrical changes followed by cloud base changes. These observations demonstrate, for the first time, dynamically driven modification of charge within a layer-cloud. Even in weakly charged layer-clouds, redistribution of charge will modify local electric fields within the cloud and the collisional behaviour of interacting charged cloud droplets. Local field intensification may also explain previously observed electrostatic discharges in warm clouds.
- Published
- 2019
- Full Text
- View/download PDF
6. Evidence for Large Increases in Clear‐Air Turbulence Over the Past Four Decades
- Author
-
Mark C. Prosser, Paul D. Williams, Graeme J. Marlton, and R. Giles Harrison
- Subjects
Geophysics. Cosmic physics ,QC801-809 - Abstract
Abstract Clear‐air turbulence (CAT) is hazardous to aircraft and is projected to intensify in response to future climate change. However, our understanding of past CAT trends is currently limited, being derived largely from outdated reanalysis data. Here we analyze CAT trends globally during 1979–2020 in a modern reanalysis data set using 21 diagnostics. We find clear evidence of large increases around the midlatitudes at aircraft cruising altitudes. For example, at an average point over the North Atlantic, the total annual duration of light‐or‐greater CAT increased by 17% from 466.5 hr in 1979 to 546.8 hr in 2020, with even larger relative changes for moderate‐or greater CAT (increasing by 37% from 70.0 to 96.1 hr) and severe‐or‐greater CAT (increasing by 55% from 17.7 to 27.4 hr). Similar increases are also found over the continental USA. Our study represents the best evidence yet that CAT has increased over the past four decades.
- Published
- 2023
- Full Text
- View/download PDF
7. Miniaturized atmospheric ionization detector
- Author
-
Aplin, Karen, Briggs, Aaron, Baird, Adam, Hastings, Peter, Harrison, R. Giles, and Marlton, Graeme
- Subjects
Physics - Instrumentation and Detectors ,Physics - Atmospheric and Oceanic Physics - Abstract
A small scintillator-based detector for atmospheric ionization measurements has been developed, partly in response to a need for better ionization data in the weather-forming regions of the atmosphere and partly with the intention of producing a commercially available device. The device can measure both the count rate and energy of atmospheric ionizing radiation. Here we report results of a test flight over the UK in December 2017 where the detector was flown with two Geiger counters on a meteorological radiosonde. The count rate profile with height was consistent both with the Geigers and with previous work. The energy of incoming ionizing radiation increased substantially with altitude., Comment: Proc 18th Conference on Atmospheric Electricity, Nara, Japan, June 2018
- Published
- 2018
8. Genomic subtyping and therapeutic targeting of acute erythroleukemia
- Author
-
Iacobucci, Ilaria, Wen, Ji, Meggendorfer, Manja, Choi, John K, Shi, Lei, Pounds, Stanley B, Carmichael, Catherine L, Masih, Katherine E, Morris, Sarah M, Lindsley, R Coleman, Janke, Laura J, Alexander, Thomas B, Song, Guangchun, Qu, Chunxu, Li, Yongjin, Payne-Turner, Debbie, Tomizawa, Daisuke, Kiyokawa, Nobutaka, Valentine, Marcus, Valentine, Virginia, Basso, Giuseppe, Locatelli, Franco, Enemark, Eric J, Kham, Shirley KY, Yeoh, Allen EJ, Ma, Xiaotu, Zhou, Xin, Sioson, Edgar, Rusch, Michael, Ries, Rhonda E, Stieglitz, Elliot, Hunger, Stephen P, Wei, Andrew H, To, L Bik, Lewis, Ian D, D’Andrea, Richard J, Kile, Benjamin T, Brown, Anna L, Scott, Hamish S, Hahn, Christopher N, Marlton, Paula, Pei, Deqing, Cheng, Cheng, Loh, Mignon L, Ebert, Benjamin L, Meshinchi, Soheil, Haferlach, Torsten, and Mullighan, Charles G
- Subjects
Agricultural ,Veterinary and Food Sciences ,Biological Sciences ,Bioinformatics and Computational Biology ,Genetics ,Agricultural Biotechnology ,Human Genome ,Pediatric ,Clinical Research ,Rare Diseases ,Pediatric Cancer ,Orphan Drug ,Hematology ,Childhood Leukemia ,Precision Medicine ,Cancer ,Biotechnology ,Cancer Genomics ,2.1 Biological and endogenous factors ,4.1 Discovery and preclinical testing of markers and technologies ,Adolescent ,Adult ,Child ,Child ,Preschool ,Female ,Genomics ,Homeodomain Proteins ,Humans ,Infant ,Infant ,Newborn ,Leukemia ,Erythroblastic ,Acute ,Male ,Mutation ,Myeloid-Lymphoid Leukemia Protein ,Nuclear Proteins ,Nucleophosmin ,Prognosis ,Tumor Suppressor Protein p53 ,Young Adult ,fms-Like Tyrosine Kinase 3 ,Medical and Health Sciences ,Developmental Biology ,Agricultural biotechnology ,Bioinformatics and computational biology - Abstract
Acute erythroid leukemia (AEL) is a high-risk leukemia of poorly understood genetic basis, with controversy regarding diagnosis in the spectrum of myelodysplasia and myeloid leukemia. We compared genomic features of 159 childhood and adult AEL cases with non-AEL myeloid disorders and defined five age-related subgroups with distinct transcriptional profiles: adult, TP53 mutated; NPM1 mutated; KMT2A mutated/rearranged; adult, DDX41 mutated; and pediatric, NUP98 rearranged. Genomic features influenced outcome, with NPM1 mutations and HOXB9 overexpression being associated with a favorable prognosis and TP53, FLT3 or RB1 alterations associated with poor survival. Targetable signaling mutations were present in 45% of cases and included recurrent mutations of ALK and NTRK1, the latter of which drives erythroid leukemogenesis sensitive to TRK inhibition. This genomic landscape of AEL provides the framework for accurate diagnosis and risk stratification of this disease, and the rationale for testing targeted therapies in this high-risk leukemia.
- Published
- 2019
9. Measuring ionizing radiation in the atmosphere with a new balloon-borne detector
- Author
-
Aplin, Karen L, Briggs, Aaron A, Harrison, R Giles, and Marlton, Graeme J
- Subjects
Physics - Instrumentation and Detectors ,Physics - Atmospheric and Oceanic Physics - Abstract
Increasing interest in energetic particle effects on weather and climate has motivated development of a miniature scintillator-based detector intended for deployment on meteorological radiosondes or unmanned airborne vehicles. The detector was calibrated with laboratory gamma sources up to 1.3 MeV, and known gamma peaks from natural radioactivity of up to 2.6 MeV. The specifications of our device in combination with the performance of similar devices suggest that it will respond to up to 17 MeV gamma rays. Laboratory tests show the detector can measure muons at the surface, and it is also expected to respond to other ionizing radiation including, for example, protons, electrons (>100 keV) and energetic helium nuclei from cosmic rays or during space weather events. Its estimated counting error is about 10%. Recent tests, when the detector was integrated with a meteorological radiosonde system, and carried on a balloon to ~25 km altitude, identified the transition region between energetic particles near the surface, which are dominated by terrestrial gamma emissions, to higher-energy particles in the free troposphere.
- Published
- 2017
- Full Text
- View/download PDF
10. On the quality of RS41 radiosonde descent data
- Author
-
B. Ingleby, M. Motl, G. Marlton, D. Edwards, M. Sommer, C. von Rohden, H. Vömel, and H. Jauhiainen
- Subjects
Environmental engineering ,TA170-171 ,Earthwork. Foundations ,TA715-787 - Abstract
Radiosonde descent profiles have been available from tens of stations for several years now – mainly from Vaisala RS41 radiosondes. They have been compared with the ascent profiles, with ECMWF short-range forecasts and with co-located radio occultation retrievals. Over this time, our understanding of the data has grown, and the comparison has also shed some light on radiosonde ascent data. The fall rate is very variable and is an important factor, with high fall rates being associated with temperature biases, especially at higher altitudes. Ascent winds are affected by pendulum motion; on average, descent winds are less affected by pendulum motion and are smoother. It is plausible that the true wind variability in the vertical lies between that shown by ascent and descent profiles. This discrepancy indicates the need for reference wind measurements. With current processing, the best results are for radiosondes with parachutes and pressure sensors. Some of the wind, temperature and humidity data are now assimilated in the ECMWF forecast system.
- Published
- 2022
- Full Text
- View/download PDF
11. Using a network of temperature lidars to identify temperature biases in the upper stratosphere in ECMWF reanalyses
- Author
-
G. Marlton, A. Charlton-Perez, G. Harrison, I. Polichtchouk, A. Hauchecorne, P. Keckhut, R. Wing, T. Leblanc, and W. Steinbrecht
- Subjects
Physics ,QC1-999 ,Chemistry ,QD1-999 - Abstract
To advance our understanding of the stratosphere, high-quality observational datasets of the stratosphere are needed. It is commonplace that reanalysis datasets are used to conduct stratospheric studies. However, the accuracy of these reanalyses at these heights is hard to infer due to a lack of in situ measurements. Satellite measurements provide one source of temperature information. As some satellite information is already assimilated into reanalyses, the direct comparison of satellite temperatures to the reanalysis is not truly independent. Stratospheric lidars use Rayleigh scattering to measure density in the middle and upper atmosphere, allowing temperature profiles to be derived for altitudes from 30 km (where Mie scattering due to stratospheric aerosols becomes negligible) to 80–90 km (where the signal-to-noise ratio begins to drop rapidly). The Network for the Detection of Atmospheric Composition Change (NDACC) contains several lidars at different latitudes that have measured atmospheric temperatures since the 1970s, resulting in a long-running upper-stratospheric temperature dataset. These temperature datasets are useful for validating reanalysis datasets in the stratosphere, as they are not assimilated into reanalyses. Here, stratospheric temperature data from lidars in the Northern Hemisphere between 1990–2017 were compared with the European Centre for Medium-Range Weather Forecasts ERA-Interim and ERA5 reanalyses. To give confidence to any bias found, temperature data from NASA's EOS Microwave Limb Sounder were also compared to ERA-Interim and ERA5 at points over the lidar sites. In ERA-Interim a cold bias of −3 to −4 K between 10 and 1 hPa was found when compared to both measurement systems. Comparisons with ERA5 found a small bias of magnitude 1 K which varies between cold and warm bias with height between 10 and 1 hPa, indicating a good thermal representation of the middle atmosphere up to 1 hPa. A further comparison was undertaken looking at the temperature bias by year to see the effects of the assimilation of the Advanced Microwave Sounding Unit-A (AMSU-A) satellite data and the Constellation Observing System for Meteorology, Ionosphere, and Climate GPS Radio Occultation (COSMIC GPSRO) data on stratospheric temperatures within the aforementioned ERA analyses. It was found that ERA5 was sensitive to the introduction of COSMIC GPSRO in 2007 with the reduction of the cold bias above 1 hPa. In addition to this, the introduction of AMSU-A data caused variations in the temperature bias between 1–10 hPa between 1997–2008.
- Published
- 2021
- Full Text
- View/download PDF
12. Identifying the nature and extent of public and donor concern about the commercialisation of biobanks for genomic research
- Author
-
Critchley, Christine R., Fleming, Jennifer, Nicol, Dianne, Marlton, Paula, Ellis, Megan, Devereux, Lisa, Bruce, Gordana, and Kerridge, Ian
- Published
- 2021
- Full Text
- View/download PDF
13. Seeing the Unseen: The Structural Influence of the Lone Pair Electrons in PbWO4.
- Author
-
Mullens, Bryce G., Marlton, Frederick P., Nicholas, Maria K., Permana, Ahmadi Jaya, Avdeev, Maxim, Mukherjee, Supratik, Vaitheeswaran, Ganapathy, Li, Cheng, Liu, Jue, Chater, Philip A., and Kennedy, Brendan J.
- Published
- 2024
- Full Text
- View/download PDF
14. Tetrahedra Rotational and Displacive Disorder in the Scheelite-Type Oxide CsReO4.
- Author
-
Mullens, Bryce G., Marlton, Frederick P., Saura-Múzquiz, Matilde, Chater, Philip A., and Kennedy, Brendan J.
- Published
- 2024
- Full Text
- View/download PDF
15. Modifying natural droplet systems by charge injection
- Author
-
R. Giles Harrison, Graeme J. Marlton, Maarten H. P. Ambaum, and Keri A. Nicoll
- Subjects
Physics ,QC1-999 - Abstract
Modifying droplet behavior has wide applications, from removing pathogens to increasing rainfall. In an environmental experiment, negative charge release is demonstrated to influence a natural fog. During charge emission, the average mass concentration of 1 μm droplets increased by 95.3%. For smaller droplets, concentrations during charge emission exceeded those without charge emission at the 99% confidence level. This is consistent with charge both facilitating formation of small droplets and inhibiting their evaporation. Physics-based droplet modification has immediate relevance to weather modification and, conceivably, pathogen control, without the introduction of additional chemical materials.
- Published
- 2022
- Full Text
- View/download PDF
16. Developing the hertz art–science project to allow inaudible sounds of the Earth and cosmos to be experienced
- Author
-
G. J. Marlton and J. Robson
- Subjects
Geography. Anthropology. Recreation ,Science - Abstract
The Earth and atmosphere are in constant motion. Volcanoes, glaciers, earthquakes, thunderstorms, and even the aurora borealis produce powerful low-frequency sounds known as infrasound. Infrasound is constantly passing through our atmosphere at frequencies of less than 20 Hz, below the range of human hearing, which is effectively an inaudible symphony. Inspired by wanting to allow physical access to this natural phenomenon, a collaboration between the worlds of contemporary art and meteorology has been developed. This led to a project called hertz, named after the 19th century physicist Heinrich Hertz, whose surname provides the scientific unit (Hz) for frequency. Hertz explores the manifestation of the hidden vibrations of our own planet and the secret harmonies of our stars. The manifestation of the hidden vibrations of our own planet was principally achieved using a subwoofer and furniture adapted to vibrate to the amplitude of infrasonic waves from pre-recorded sources and in real time. The project's motivations are to explore new methods for experiencing and re-engaging with parts of our planet through this phenomenon. Hertz has had a UK national tour in which 7000 people interacted with the piece, of which approximately 85 % felt more reconnected to the environment after interacting with the installation. This paper describes the concepts, creative ideas, technology, and science behind the project. It addresses its development, including the steps to make it accessible for all, and examines its impact on those who created and interacted with the work.
- Published
- 2020
- Full Text
- View/download PDF
17. Evaluation of ARM tethered-balloon system instrumentation for supercooled liquid water and distributed temperature sensing in mixed-phase Arctic clouds
- Author
-
D. Dexheimer, M. Airey, E. Roesler, C. Longbottom, K. Nicoll, S. Kneifel, F. Mei, R. G. Harrison, G. Marlton, and P. D. Williams
- Subjects
Environmental engineering ,TA170-171 ,Earthwork. Foundations ,TA715-787 - Abstract
A tethered-balloon system (TBS) has been developed and is being operated by Sandia National Laboratories (SNL) on behalf of the U.S. Department of Energy's (DOE) Atmospheric Radiation Measurement (ARM) User Facility in order to collect in situ atmospheric measurements within mixed-phase Arctic clouds. Periodic tethered-balloon flights have been conducted since 2015 within restricted airspace at ARM's Advanced Mobile Facility 3 (AMF3) in Oliktok Point, Alaska, as part of the AALCO (Aerial Assessment of Liquid in Clouds at Oliktok), ERASMUS (Evaluation of Routine Atmospheric Sounding Measurements using Unmanned Systems), and POPEYE (Profiling at Oliktok Point to Enhance YOPP Experiments) field campaigns. The tethered-balloon system uses helium-filled 34 m3 helikites and 79 and 104 m3 aerostats to suspend instrumentation that is used to measure aerosol particle size distributions, temperature, horizontal wind, pressure, relative humidity, turbulence, and cloud particle properties and to calibrate ground-based remote sensing instruments. Supercooled liquid water content (SLWC) sondes using the vibrating-wire principle, developed by Anasphere Inc., were operated at Oliktok Point at multiple altitudes on the TBS within mixed-phase clouds for over 200 h. Sonde-collected SLWC data were compared with liquid water content derived from a microwave radiometer, Ka-band ARM zenith radar, and ceilometer at the AMF3, as well as liquid water content derived from AMF3 radiosonde flights. The in situ data collected by the Anasphere sensors were also compared with data collected simultaneously by an alternative SLWC sensor developed at the University of Reading, UK; both vibrating-wire instruments were typically observed to shed their ice quickly upon exiting the cloud or reaching maximum ice loading. Temperature sensing measurements distributed with fiber optic tethered balloons were also compared with AMF3 radiosonde temperature measurements. Combined, the results indicate that TBS-distributed temperature sensing and supercooled liquid water measurements are in reasonably good agreement with remote sensing and radiosonde-based measurements of both properties. From these measurements and sensor evaluations, tethered-balloon flights are shown to offer an effective method of collecting data to inform and constrain numerical models, calibrate and validate remote sensing instruments, and characterize the flight environment of unmanned aircraft, circumventing the difficulties of in-cloud unmanned aircraft flights such as limited flight time and in-flight icing.
- Published
- 2019
- Full Text
- View/download PDF
18. P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
- Author
-
M. Dimopoulos, S. Opat, S. D’Sa, W. Jurczak, H.-P. Lee, G. Cull, R. G. Owen, P. Marlton, B. E. Wahlin, R. Garcia-Sanz, H. McCarthy, S. Mulligan, A. Tedeschi, J. J. Castillo, J. Czyz, C. Fernandez De Larrea Rodriguez, D. Belada, E. Libby, J. Matous, M. Motta, T. Siddiqi, M. Tani, M. Trneny, M. Minnema, C. Buske, V. Leblond, S. P. Treon, J. Trotman, W. Y. Chan, J. Schneider, H. Allewelt, A. Cohen, J. Huang, and C. S. Tam
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
19. Relaxor behavior and electrothermal properties of Sn- and Nb-modified (Ba,Ca)TiO3 Pb-free ferroelectric
- Author
-
Venkateshwarlu, Sarangi, Nayak, Sanjib, Marlton, Frederick P., Weyland, Florian, Novak, Nikola, Maurya, Deepam, Veerabhadraiah, Yashaswini, Borkiewicz, Olaf, Beyer, Kevin A., Jørgensen, Mads R. V., and Pramanick, Abhijit
- Published
- 2020
- Full Text
- View/download PDF
20. Variable Temperature In Situ Neutron Powder Diffraction and Conductivity Studies of Undoped HoNbO4 and HoTaO4.
- Author
-
Mullens, Bryce G., Saura-Múzquiz, Matilde, Cordaro, Giulio, Marlton, Frederick P., Maynard-Casely, Helen E., Zhang, Zhaoming, Baldinozzi, Gianguido, and Kennedy, Brendan J.
- Published
- 2024
- Full Text
- View/download PDF
21. Photophysical Studies of Helicate and Mesocate Double-Stranded Dinuclear Ru(II) Complexes.
- Author
-
Xu, Xinyue, Marlton, Samuel J. P., Flint, Kate L., Hudson, Rohan J., Keene, F. Richard, Hall, Christopher R., and Smith, Trevor A.
- Published
- 2024
- Full Text
- View/download PDF
22. Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome.
- Author
-
Ahmed Mohamed, Joel Collins, Hui Jiang, Jeffrey Molendijk, Thomas Stoll, Federico Torta, Markus R Wenk, Robert J Bird, Paula Marlton, Peter Mollee, Kate A Markey, and Michelle M Hill
- Subjects
Medicine ,Science - Abstract
BACKGROUND:Multiple myeloma (MM) is a hematological malignancy characterized by the clonal expansion of malignant plasma cells. Though durable remissions are possible, MM is considered incurable, with relapse occurring in almost all patients. There has been limited data reported on the lipid metabolism changes in plasma cells during MM progression. Here, we evaluated the feasibility of concurrent lipidomics and proteomics analyses from patient plasma cells, and report these data on a limited number of patient samples, demonstrating the feasibility of the method, and establishing hypotheses to be evaluated in the future. METHODS:Plasma cells were purified from fresh bone marrow aspirates using CD138 microbeads. Proteins and lipids were extracted using a bi-phasic solvent system with methanol, methyl tert-butyl ether, and water. Untargeted proteomics, untargeted and targeted lipidomics were performed on 7 patient samples using liquid chromatography-mass spectrometry. Two comparisons were conducted: high versus low risk; relapse versus newly diagnosed. Proteins and pathways enriched in the relapsed group was compared to a public transcriptomic dataset from Multiple Myeloma Research Consortium reference collection (n = 222) at gene and pathways level. RESULTS:From one million purified plasma cells, we were able to extract material and complete untargeted (~6000 and ~3600 features in positive and negative mode respectively) and targeted lipidomics (313 lipids), as well as untargeted proteomics analysis (~4100 reviewed proteins). Comparative analyses revealed limited differences between high and low risk groups (according to the standard clinical criteria), hence we focused on drawing comparisons between the relapsed and newly diagnosed patients. Untargeted and targeted lipidomics indicated significant down-regulation of phosphatidylcholines (PCs) in relapsed MM. Although there was limited overlap of the differential proteins/transcripts, 76 significantly enriched pathways in relapsed MM were common between proteomics and transcriptomics data. Further evaluation of transcriptomics data for lipid metabolism network revealed enriched correlation of PC, ceramide, cardiolipin, arachidonic acid and cholesterol metabolism pathways to be exclusively correlated among relapsed but not in newly-diagnosed patients. CONCLUSIONS:This study establishes the feasibility and workflow to conduct integrated lipidomics and proteomics analyses on patient-derived plasma cells. Potential lipid metabolism changes associated with MM relapse warrant further investigation.
- Published
- 2020
- Full Text
- View/download PDF
23. Variable Temperature In Situ Neutron Powder Diffraction and Conductivity Studies of Undoped HoNbO4and HoTaO4
- Author
-
Mullens, Bryce G., Saura-Múzquiz, Matilde, Cordaro, Giulio, Marlton, Frederick P., Maynard-Casely, Helen E., Zhang, Zhaoming, Baldinozzi, Gianguido, and Kennedy, Brendan J.
- Abstract
Neutron powder diffraction data has been used to quantify the monoclinic (space group I2/a) to tetragonal (I41/a) phase transition that occurs at 775 °C in HoNbO4and 1300 °C in HoTaO4. In both cases, deviation from second-order behavior is evident. The LnTaO4(Ln = Tb–Er) family of oxides has the potential to adopt one of monoclinic, I2/aor P2/c, structures depending on the synthesis conditions. The monoclinic P2/cpolymorph of HoTaO4undergoes an irreversible first-order phase transition to the high-temperature I41/ascheelite-type structure upon heating, with the monoclinic I2/aphase recovered upon cooling. This is the first direct evidence of this irreversible phase transition and implies a maximum heating temperature to synthesize the P2/cphase for potential ionic conductivity applications. Heating a green powder mixture of Ho2O3+ Ta2O5revealed a complex series of phase transformations, including the observation of a weberite-type Ho3TaO7intermediate between 1200 and 1390 °C that was not observed upon cooling. Coupled with electrochemical impedance spectroscopy measurements, this diffraction data provides a structural model that explains the higher mobility of charge carriers in LnTaO4materials that can be used to identify dopants and improve their ionic conductivity and applicability. Undoped HoNbO4and HoTaO4are poor conductors, and the activation energy of tetragonal HoNbO4is greater than that of the monoclinic polymorphs. Oxygen ion and proton conductivities of the undoped structures occur via interstitial oxygen sites (∼10–6S cm–1at 800 °C), providing a potential avenue to improve their application in practical devices such as solid oxide fuel cells.
- Published
- 2024
- Full Text
- View/download PDF
24. Large electromechanical strain and unconventional domain switching near phase convergence in a Pb-free ferroelectric
- Author
-
Venkateshwarlu, Sarangi, Venkataraman, Lalitha K., Segouin, Valentin, Marlton, Frederick P., Hin, Ho Chin, Chernyshov, Dmitry, Ren, Yang, Jørgensen, Mads R. V., Nayak, Sanjib, Rödel, Jürgen, Daniel, Laurent, and Pramanick, Abhijit
- Published
- 2020
- Full Text
- View/download PDF
25. Gas-Phase Phenyl Radical + O2 Reacts via a Submerged Transition State.
- Author
-
Shiels, Oisin J., Marlton, Samuel J. P., Poad, Berwyck L. J., Blanksby, Stephen J., da Silva, Gabriel, and Trevitt, Adam J.
- Published
- 2024
- Full Text
- View/download PDF
26. Characteristics of Desert Precipitation in the UAE Derived from a Ceilometer Dataset
- Author
-
Martin W. Airey, Keri A. Nicoll, R. Giles Harrison, and Graeme J. Marlton
- Subjects
cloud droplets ,drought ,ceilometer ,UAE ,evaporation ,virga ,Meteorology. Climatology ,QC851-999 - Abstract
Understanding rainfall in arid and water-scarce regions is central to the efficient use of water resources in agriculture, irrigation, and domestic food security. This work presents a new dataset with which to study precipitation processes in arid regions, utilising two years (2018–2020) of ceilometer observations made at Al Ain International Airport in the desert region of Al Ain, United Arab Emirates (UAE), where the annual rainfall is 76 mm. Ceilometer data provide a novel method by which to study both the evolution of water droplets from the cloud base down to the surface and the local circumstances required for rain to successfully reach the surface. In this work, we explore how successful precipitation depends on the initial size of the droplets and the thermodynamic profile below the cloud. For 64 of the 105 rain events, the droplet diameters ranged from 0.60 to 3.75 mm, with a mean of 1.84 mm. We find that smaller droplets, higher cloud bases, reduced cloud depths, and colder cloud bases all act to prevent successful precipitation, instead yielding virga (28 out of the 105 rain generating events). We identify how these multiple regional factors combine—specifically, we identify clouds deeper than 2.9 km, droplet diameters greater than 2 mm, and a midpoint below-cloud RH profile greater than 50%—to give successful rainfall, which may ultimately lead to more efficient rainfall enhancing measures, such as cloud seeding.
- Published
- 2021
- Full Text
- View/download PDF
27. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML:a randomized, placebo-controlled study by the ALLG.
- Author
-
Loo, S, Roberts, AW, Anstee, NS, Kennedy, GA, He, SZ-X, Schwarer, AP, Enjeti, AK, D'Rozario, J, Marlton, P, Bilmon, I, Taper, JM, Cull, G, Tiley, C, Verner, E, Hahn, U, Hiwase, DK, Iland, HJ, Murphy, NE, Ramanathan, S, Reynolds, J, Ong, DM, Tiong, IS, Wall, M, Murray, M, Rawling, T, Leadbetter, J, Rowley, L, Latimer, M, Yuen, SLS, Ting, SB, Fong, CY, Morris, KL, Bajel, A, Seymour, JF, Levis, MJ, Wei, AH, Loo, S, Roberts, AW, Anstee, NS, Kennedy, GA, He, SZ-X, Schwarer, AP, Enjeti, AK, D'Rozario, J, Marlton, P, Bilmon, I, Taper, JM, Cull, G, Tiley, C, Verner, E, Hahn, U, Hiwase, DK, Iland, HJ, Murphy, NE, Ramanathan, S, Reynolds, J, Ong, DM, Tiong, IS, Wall, M, Murray, M, Rawling, T, Leadbetter, J, Rowley, L, Latimer, M, Yuen, SLS, Ting, SB, Fong, CY, Morris, KL, Bajel, A, Seymour, JF, Levis, MJ, and Wei, AH
- Abstract
Sorafenib maintenance improves outcome after hematopoietic cell transplant (HCT) for patients with FLT3-ITD acute myeloid leukemia (AML). Although promising outcomes have been reported for sorafenib plus intensive chemotherapy, randomized data are limited. This placebo-controlled, phase 2 study (ACTRN12611001112954) randomized 102 patients 18-65 years (2:1) to sorafenib vs placebo (days 4-10) combined with intensive induction; idarubicin 12mg/m2 days 1-3 plus cytarabine 1.5g/m2 twice daily on days 1,3,5,7 (18-55 years) or 100mg/m2 days 1-7 (56-65 years), consolidation therapy, followed by maintenance treatment for 12 months (post-HCT excluded) in newly diagnosed FLT3-ITD AML. Four patients were excluded from modified intention-to-treat final analysis (3 not dosed and 1 later found to be FLT3-ITD negative). Rates of complete remission (CR)/CR with incomplete hematologic recovery (CR/CRi) were high in both arms (sorafenib 78%/9%, placebo 70%/24%). With 49.1 months median follow-up, the primary endpoint of event-free survival (EFS) was not improved by sorafenib (2-year EFS 47.9% vs 45.4%)(hazard ratio [HR] 0.87;95% confidence interval [CI] 0.51-1.51, p=0.61). Two-year overall survival (OS) was 67% in the sorafenib arm and 58% in the placebo arm (HR 0.76; 95% CI 0.42-1.39). For patients transplanted in first remission, 2-year OS was 84% and 67% in the sorafenib and placebo arms, respectively (HR 0.45;95% CI 0.18-1.12, p=0.08). In exploratory analyses, FLT3-ITD measurable residual disease negative status (<0.001%) post-induction was associated with improved 2-year OS (83% vs 60%) (HR 0.4;95% CI 0.17-0.93, p=0.028). In conclusion, routine use of pre-transplant sorafenib plus chemotherapy in unselected patients with FLT3-ITD AML is not supported by this study.
- Published
- 2023
28. A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML
- Author
-
Anthony P. Schwarer, Jason Butler, Kathryn Jackson, Ashanka Beligaswatte, Louisa Martin, Glen Kennedy, Zantomio Daniela, Ian Lewis, Devendra Hiwase, Joel Wight, Simon He, Andrew Grigg, Kirk Morris, Peter Mollee, and Paula Marlton
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract. The proportion of patients with acute myeloid leukemia (AML) cured is increased by administering high-dose cytarabine (HiDAC). It remains uncertain whether to administer HiDAC as induction or consolidation, and whether ≥1 cycle of HiDAC is required. Our retrospective study of 416 adult AML patients, excluding good risk cytogenetics, compared a single cycle of HiDAC-based therapy followed by 2 cycles of standard-dose cytarabine (SDAC) (HiDAC induction cohort) with SDAC-based chemotherapy followed by 2 cycles of HiDAC-based chemotherapy (HiDAC consolidation cohort). Complete remission (CR) rate was greater in the HiDAC induction cohort (90% vs 78%, P
- Published
- 2018
- Full Text
- View/download PDF
29. A Structural Study of 0.06LiNbO3-0.94K0.5Na0.5NbO3 from Neutron Total Scattering Analysis
- Author
-
J. Kong, J. Liu, F. Marlton, M. R. V. Jørgensen, and A. Pramanick
- Subjects
ferroelectrics ,total scattering ,neutron diffraction ,local structure ,Crystallography ,QD901-999 - Abstract
The structure of ferroelectric 0.06LiNbO3-0.94K0.5Na0.5NbO3 (KNNL6) was investigated by the neutron total scattering method in the temperature range of 290–773 K. The Rietveld analysis using the powder neutron diffraction data in the range of 290–773 K indicates transition from a two-phase (monoclinic and tetragonal) mixture at room temperature to tetragonal and cubic phases at higher temperatures. However, characterization of the local structure by the pair distribution function (PDF) method indicates that the local structure (r ≲ 10 Å) stays monoclinic over the same temperature range. Besides, the local oxygen octahedral distortion exhibits smaller changes with temperature than what is observed for the long-range average structure.
- Published
- 2021
- Full Text
- View/download PDF
30. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
- Author
-
Dimopoulos, Meletios A., Opat, Stephen, D'Sa, Shirley, Jurczak, Wojciech, Lee, Hui-Peng, Cull, Gavin, Owen, Roger G., Marlton, Paula, Wahlin, Björn E., Garcia-Sanz, Ramon, McCarthy, Helen, Mulligan, Stephen, Tedeschi, Alessandra, Castillo, Jorge J., Czyz, Jaroslaw, Fernández de Larrea, Carlos, Belada, David, Libby, Edward, Matous, Jeffrey, and Motta, Marina
- Published
- 2023
- Full Text
- View/download PDF
31. Consistent dust electrification from Arabian Gulf sea breezes
- Author
-
Keri Nicoll, Giles Harrison, Graeme Marlton, and Martin Airey
- Subjects
charge ,electric field ,aerosol and atmospheric electricity ,Environmental technology. Sanitary engineering ,TD1-1066 ,Environmental sciences ,GE1-350 ,Science ,Physics ,QC1-999 - Abstract
The Arabian Gulf region experiences regular thermally driven sea breeze circulations which occur all year round, penetrating hundreds of kilometres inland. As a sea breeze front moves inland, substantial electric fields are generated by separation of charged desert dust. In the first surface electric field measurements made in the United Arab Emirates (UAE), consistent and repeatable substantial electric field changes with magnitudes up to 7 kV m ^−1 have been detected at Al Ain (170 km from the western coast), during 80 separate sea breeze events in 2018. Every sea breeze frontal passage shows the same characteristic signature of a transient maximum peak in electric field lasting tens of minutes. Electric field changes during these events were always negative (i.e. enhancing the existing negative ‘fair weather’ electric field), in contrast to many other reported observations in dust storms in which conditions were less repeatable. The regular and substantial dust electrification found demonstrates that accurate representation of dust in climate and weather models requires electrical effects to be addressed, both in the generation process, and by considering aggregates in radiative transfer calculations as electrically aligned rather than randomly ordered. Furthermore, satellite aerosol retrievals are affected by the changed attenuation of electromagnetic radiation when dust particles are charged, for which corrections may be needed.
- Published
- 2020
- Full Text
- View/download PDF
32. Protonation Isomer Specific Ion–Molecule Radical Reactions.
- Author
-
Shiels, Oisin J., Marlton, Samuel J. P., and Trevitt, Adam J.
- Published
- 2023
- Full Text
- View/download PDF
33. Rare variants in Fanconi anemia genes are enriched in acute myeloid leukemia
- Author
-
Maung, Kyaw Ze Ya, Leo, Paul J., Bassal, Mahmoud, Casolari, Debora A., Gray, James X, Bray, Sarah C., Pederson, Stephen, Singhal, Deepak, Samaraweera, Saumya E., Nguyen, Tran, Cildir, Gökhan, Marshall, Mhairi, Ewing, Adam, Duncan, Emma L., Brown, Matthew A., Saal, Russell, Tergaonkar, Vinay, To, Luen Bik, Marlton, Paula, Gill, Devinder, Lewis, Ian, Deans, Andrew J, Brown, Anna L, D’Andrea, Richard J, and Gonda, Thomas J
- Published
- 2018
- Full Text
- View/download PDF
34. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
- Author
-
Andrew Grigg, Martin J.S. Dyer, Marcos González Díaz, Martin Dreyling, Simon Rule, Guiyuan Lei, Andrea Knapp, Elisabeth Wassner-Fritsch, and Paula Marlton
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
The GAUDI study assessed safety and preliminary efficacy of induction therapy with obinutuzumab plus chemotherapy, followed by maintenance therapy with obinutuzumab alone, in previously untreated patients with follicular lymphoma. Assignment to chemotherapy was decided on a per-center basis before the patients’ enrollment. Patients (n=81) received four to six cycles of obinutuzumab plus bendamustine every 4 weeks or six to eight cycles of obinutuzumab plus CHOP every 3 weeks. Patients with an end-of-treatment response were eligible for obinutuzumab maintenance therapy every 3 months for 2 years or until disease progression. Induction treatment was completed by 90% of patients in the obinutuzumab plus bendamustine group and 95% in the obinutuzumab plus CHOP group, while maintenance was completed by 81% and 72% of patients, respectively. All patients experienced at least one adverse event during induction, most commonly infusion-related reactions (58%), the majority of which were grade 1/2. The most common hematologic adverse event was grade 3/4 neutropenia (36% during induction and 7% during maintenance). One treatment-related death occurred during the maintenance phase. At the end of induction, 94% of patients had achieved an overall response, with complete response based on computed tomography in 36%. The progression-free survival rate at 36 months was 90% in the obinutuzumab plus bendamustine group and 84% in the obinutuzumab plus CHOP group. These results demonstrate that induction therapy with obinutuzumab plus bendamustine or obinutuzumab plus CHOP, followed by obinutuzumab maintenance, is associated with tolerable safety and promising efficacy. This study is registered at ClinicalTrials.gov as NCT00825149.
- Published
- 2017
- Full Text
- View/download PDF
35. The Perspectives of Haematological Cancer Patients on Tissue Banking
- Author
-
Turon, Heidi, Waller, Amy, Clinton-McHarg, Tara, Boyes, Allison, Fleming, Jennifer, Marlton, Paula, Harrison, Simon J., and Sanson-Fisher, Rob
- Published
- 2016
- Full Text
- View/download PDF
36. P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
- Author
-
Dimopoulos, M., primary, Opat, S., additional, D’Sa, S., additional, Jurczak, W., additional, Lee, H.-P., additional, Cull, G., additional, Owen, R. G., additional, Marlton, P., additional, Wahlin, B. E., additional, Garcia-Sanz, R., additional, McCarthy, H., additional, Mulligan, S., additional, Tedeschi, A., additional, Castillo, J. J., additional, Czyz, J., additional, Fernandez De Larrea Rodriguez, C., additional, Belada, D., additional, Libby, E., additional, Matous, J., additional, Motta, M., additional, Siddiqi, T., additional, Tani, M., additional, Trneny, M., additional, Minnema, M., additional, Buske, C., additional, Leblond, V., additional, Treon, S. P., additional, Trotman, J., additional, Chan, W. Y., additional, Schneider, J., additional, Allewelt, H., additional, Cohen, A., additional, Huang, J., additional, and Tam, C. S., additional
- Published
- 2022
- Full Text
- View/download PDF
37. ASPEN: Results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrom Macroglobulinemia (WM).
- Author
-
Buske C., Dimopoulos M., Opat S., D'Sa S., Jurczak W., Lee H.-P., Cull G., Owen R.G., Marlton P., Wahlin B.E., Garcia Sanz R., McCarthy H., Mulligan S., Tedeschi A., Castillo J., Czyz J., Fernandez De Larrea C., Belada D., Libby E., Matous J., Motta M., Siddiqi T., Tani M., Trneny M., Minnema M., Leblond V., Chan W.Y., Schneider J., Cohen A., Huang J., Tam C.S., Buske C., Dimopoulos M., Opat S., D'Sa S., Jurczak W., Lee H.-P., Cull G., Owen R.G., Marlton P., Wahlin B.E., Garcia Sanz R., McCarthy H., Mulligan S., Tedeschi A., Castillo J., Czyz J., Fernandez De Larrea C., Belada D., Libby E., Matous J., Motta M., Siddiqi T., Tani M., Trneny M., Minnema M., Leblond V., Chan W.Y., Schneider J., Cohen A., Huang J., and Tam C.S.
- Abstract
Introduction: Bruton's tyrosine kinase (BTK) inhibition is an emerging standard of care for WM. The ASPEN trial (NCT03053440) is a randomized phase 3 study comparing zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with WM. Method(s): Patients with MYD88 mutation-positive (MYD88mut+) WM were randomly assigned 1:1 to receive zanubrutinib (160 mg twice daily) or ibrutinib (420 mg once daily). Patients without MYD88 mutations were assigned to a separate cohort, received zanubrutinib, and are reported separately. Randomization was stratified by CXCR4 mutational status and the number of lines of prior therapy (0 vs 1-3 vs >3). The primary end point was the proportion of patients achieving a complete response or very good partial response (CR+VGPR). Sample size was calculated to provide 81% power to detect a difference in CR+VGPR rate of 35% vs 15% in the subset of patients with relapsed or refractory WM. Primary analysis was planned to occur at ~12 months after the last patient enrolled. Result(s): In total, 201 patients were randomized from Jan 2017 to Jul 2018. The treatment groups were well balanced for important baseline factors, with the exception of more elderly patients (aged >75 years, 33.3% vs 22.2%) and more anemia (hemoglobin <=110 g/L, 65.7% vs 53.5%) in the zanubrutinib arm. At a median follow-up of 19.4 months, the rate of VGPR (no CRs were observed) was 28.4% vs 19.2% with zanubrutinib vs ibrutinib, respectively (2-sided P=0.09). Rates of atrial fibrillation, contusion, diarrhea, edema peripheral, hemorrhage, muscle spasms, pneumonia, and adverse events leading to discontinuation or death were lower with zanubrutinib. The rate of neutropenia was higher with zanubrutinib (Table), but grade >=3 infection rates were similar (17.8% vs 19.4%). Conclusion(s): ASPEN is the largest phase 3 trial of BTK inhibitors in WM and the first head-to-head comparison of BTK inhibitors in any disease. Although
- Published
- 2022
38. ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenstrom macroglobulinemia (WM).
- Author
-
Tam C.S.L., Garcia-Sanz R., Opat S., D'Sa S., Jurczak W., Lee H.-P., Cull G., Owen R.G., Marlton P., Wahlin B.E., Tedeschi A., Castillo J.J., Siddiqi T., Buske C., Leblond V., Chan W.Y., Schneider J., Cohen A., Huang J., Dimopoulos M.A., Tam C.S.L., Garcia-Sanz R., Opat S., D'Sa S., Jurczak W., Lee H.-P., Cull G., Owen R.G., Marlton P., Wahlin B.E., Tedeschi A., Castillo J.J., Siddiqi T., Buske C., Leblond V., Chan W.Y., Schneider J., Cohen A., Huang J., and Dimopoulos M.A.
- Abstract
Background: ASPEN is a randomized, open-label, phase 3 study comparing ZANU, a potent and selective Bruton tyrosine kinase inhibitor (BTKi), with the first-generation BTKi IBR in patients with WM. We present data with a median follow-up of 43 months. Method(s): Patients with MYD88 mutations were assigned to cohort 1 and randomized 1:1 to receive ZANU 160 mg twice daily or IBR 420 mg once daily. Randomization was stratified by CXCR4 mutational status and lines of prior therapy (0 vs 1-3 vs > 3). Patients without MYD88 mutations were assigned to cohort 2 and received ZANU 160 mg twice daily. The primary endpoint was proportion of patients achieving complete response or very good partial response (CR+VGPR). Result(s): A total of 201 patients (ZANU arm, n = 102; IBR arm, n = 99) were enrolled in cohort 1 and 28 patients were enrolled in cohort 2. A larger proportion of patients in the ZANU arm of cohort 1 vs IBR had CXCR4 mutations by next-generation sequencing (32% vs 20%, or 33 of 98 vs 20 of 92 with data available) and were aged > 75 years (33% vs 22%). Median duration of treatment was 42 months (ZANU) and 41 months (IBR), with 67% and 58% remaining on treatment, respectively. The CR+VGPR rate by investigator was 36% with ZANU vs 22% with IBR (p= 0.02) in cohort 1, and 31% in cohort 2. One patient achieved CR (cohort 2). In patients with wild type or mutant CXCR4 from cohort 1, CR+VGPR rates with ZANU vs IBR were 45% vs 28% (p= 0.04) and 21% vs 5% (p= 0.15), respectively. Median progression-free survival and overall survival were not yet reached. Rates of atrial fibrillation, diarrhea, hypertension, localized infection, hemorrhage, muscle spasms, pneumonia, and adverse events leading to discontinuation or death were lower with ZANU vs IBR (Table). Exposure-adjusted incidence rates of atrial fibrillation/flutter and hypertension were lower with ZANU vs IBR (0.2 vs 0.8 and 0.5 vs 1.0 persons per 100 person-months, respectively; p< 0.05). Rate of neutropenia was higher
- Published
- 2022
39. Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia.
- Author
-
Mulligan S.P., Opat S., Marlton P., Kuss B., Gerungan P., Puig A., McGeachie M., Tam C.S., Mulligan S.P., Opat S., Marlton P., Kuss B., Gerungan P., Puig A., McGeachie M., and Tam C.S.
- Published
- 2022
40. Aspen: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (zanu) vs ibrutinib (ibr) in patients (pts) with waldenstrom macroglobulinemia (wm).
- Author
-
Dimopoulos M., Opat S., D'Sa S., Jurczak W., Lee H.-P., Cull G., Owen R.G., Marlton P., Wahlin B.E., Garcia-Sanz R., McCarthy H., Mulligan S., Tedeschi A., Castillo J.J., Czyz J., De Larrea Rodriguez C.F., Belada D., Libby E., Matous J., Motta M., Siddiqi T., Tani M., Trneny M., Minnema M., Buske C., Leblond V., Treon S.P., Trotman J., Chan W.Y., Schneider J., Allewelt H., Cohen A., Huang J., Tam C.S., Dimopoulos M., Opat S., D'Sa S., Jurczak W., Lee H.-P., Cull G., Owen R.G., Marlton P., Wahlin B.E., Garcia-Sanz R., McCarthy H., Mulligan S., Tedeschi A., Castillo J.J., Czyz J., De Larrea Rodriguez C.F., Belada D., Libby E., Matous J., Motta M., Siddiqi T., Tani M., Trneny M., Minnema M., Buske C., Leblond V., Treon S.P., Trotman J., Chan W.Y., Schneider J., Allewelt H., Cohen A., Huang J., and Tam C.S.
- Abstract
Background: ZANU is a potent and selective next-generation Bruton tyrosine kinase inhibitor (BTKi) designed to have greater affinity to BTK while minimizing off-target inhibition of TEC-and EGFR-family kinases. ASPEN (NCT03053440) is a randomized, open-label, phase 3 study comparing ZANU with the first-generation BTKi IBR in pts with WM. We present data with a median follow-up of 43 months. Aim(s): To compare the efficacy and safety of ZANU vs IBR in pts with MYD88 mutant (MYD88mut) WM and ZANU in pts with wild-type MYD88 (MYD88wt) WM. Method(s): Pts with MYD88mut WM were assigned to cohort 1 and randomized 1:1 to receive ZANU 160 mg twice daily or IBR 420 mg once daily. Pts with MYD88wt were assigned to cohort 2 and received ZANU 160 mg twice daily until disease progression. Randomization was stratified by CXCR4 mutational status by Sanger sequencing and lines of prior therapy (0, 1-3, or >3). All pts gave informed consent. The primary endpoint was proportion of pts achieving very good partial response or better (VGPR + complete response [CR]). Primary analysis occurred at 19 months median follow-up, and final analysis is planned to occur ~4 years after the first pt enrolled. Result(s): A total of 201 pts (102 ZANU; 99 IBR) were enrolled in cohort 1 and 28 pts in cohort 2. Baseline characteristics in cohort 1 differed between pts treated with ZANU vs IBR in CXCR4 mutations by next-generation sequencing (32% vs 20%, or 33 of 98 vs 20 of 92 available samples, respectively) and pts aged >75 years (33% vs 22%, respectively). Median duration of treatment was 42 months (ZANU) and 41 months (IBR), with 67% and 58% remaining on treatment, respectively. The VGPR+CR rate by investigator was 36% with ZANU vs 22% with IBR (descriptive p = 0.02) in cohort 1, and 31% in cohort 2. One pt in cohort 2 obtained a CR. In pts with wild-type (65 ZANU; 72 IBR) or mutant CXCR4 (33 ZANU; 20 IBR) from cohort 1, VGPR+CR rates with ZANU vs IBR were 45% vs 28% (p = 0.04) and 21% vs 5% (p = 0.
- Published
- 2022
41. Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study
- Author
-
Cull, G, Burger, JA, Opat, S, Gottlieb, D, Verner, E, Trotman, J, Marlton, P, Munoz, J, Johnston, P, Simpson, D, Stern, JC, Prathikanti, R, Wu, K, Novotny, W, Huang, J, Tam, CS, Cull, G, Burger, JA, Opat, S, Gottlieb, D, Verner, E, Trotman, J, Marlton, P, Munoz, J, Johnston, P, Simpson, D, Stern, JC, Prathikanti, R, Wu, K, Novotny, W, Huang, J, and Tam, CS
- Abstract
The phase I/II AU-003 study in patients with treatment-naïve (TN) or relapsed/refractory (R/R) chronic lymphocytic leukaemia/small lymphocytic lymphoma demonstrated that zanubrutinib therapy results in clinically meaningful and durable responses with acceptable safety and tolerability. We report updated safety and efficacy data for 123 patients with a median follow-up of 47·2 months. Patients received zanubrutinib 160 mg twice daily (81 patients), 320 mg once daily (40), or 160 mg once daily (two). Discontinuations due to adverse events or disease progression were uncommon. The overall response rate (ORR) was 95·9% (TN, 100%; R/R, 95%) with 18·7% achieving complete response (CR). Ongoing response at 3 years was reported in 85·7%. The ORR in patients with del(17p)/tumour protein p53 mutation was 87·5% (CR 16·7%). The 2- and 3-year progression-free survival estimates were 90% (TN, 90%; R/R, 91%) and 83% (TN, 81%; R/R, 83%) respectively. The most reported Grade ≥3 adverse events were neutropenia (15·4%), pneumonia (9·8%), hypertension (8·9%) and anaemia (6·5%). The annual incidence of atrial fibrillation, major haemorrhage, Grade ≥3 neutropenia and Grade ≥3 infection decreased over time. With a median follow-up of ~4 years, responses remain clinically meaningful and durable and long-term tolerability to zanubrutinib therapy continues.
- Published
- 2022
42. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
- Author
-
Tam, CS, Dimopoulos, M, Garcia-Sanz, R, Trotman, J, Opat, S, Roberts, AW, Owen, R, Song, Y, Xu, W, Zhu, J, Li, J, Qiu, L, D'Sa, S, Jurczak, W, Cull, G, Marlton, P, Gottlieb, D, Munoz, J, Phillips, T, Du, C, Ji, M, Zhou, L, Guo, H, Zhu, H, Chan, WY, Cohen, A, Novotny, W, Huang, J, Tedeschi, A, Tam, CS, Dimopoulos, M, Garcia-Sanz, R, Trotman, J, Opat, S, Roberts, AW, Owen, R, Song, Y, Xu, W, Zhu, J, Li, J, Qiu, L, D'Sa, S, Jurczak, W, Cull, G, Marlton, P, Gottlieb, D, Munoz, J, Phillips, T, Du, C, Ji, M, Zhou, L, Guo, H, Zhu, H, Chan, WY, Cohen, A, Novotny, W, Huang, J, and Tedeschi, A
- Abstract
Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor evaluated in multiple B-cell malignancy studies. We constructed a pooled safety analysis to better understand zanubrutinib-associated treatment-emergent adverse events (TEAEs) and identify treatment-limiting toxicities. Data were pooled from 6 studies (N = 779). Assessments included type, incidence, severity, and outcome of TEAEs. Median age was 65 years; 20% were ≥75 years old. Most patients had Waldenström macroglobulinemia (33%), chronic lymphocytic leukemia/small lymphocytic lymphoma (29%), or mantle-cell lymphoma (19%). Median treatment duration was 26 months (range, 0.1-65); 16% of patients were treated for ≥3 years. Common nonhematologic TEAEs were upper respiratory tract infection (URI, 39%), rash (27%), bruising (25%), musculoskeletal pain (24%), diarrhea (23%), cough (21%), pneumonia (21%), urinary tract infection (UTI), and fatigue (15% each). Most common grade ≥3 TEAEs were pneumonia (11%), hypertension (5%), URI, UTI, sepsis, diarrhea, and musculoskeletal pain (2% each). Atrial fibrillation and major hemorrhage occurred in 3% and 4% of patients, respectively. Atrial fibrillation, hypertension, and diarrhea occurred at lower rates than those reported historically for ibrutinib. Grade ≥3 adverse events included neutropenia (23%), thrombocytopenia (8%), and anemia (8%). Serious TEAEs included pneumonia (11%), sepsis (2%), and pyrexia (2%).Treatment discontinuations and dose reductions for adverse events occurred in 10% and 8% of patients, respectively. Thirty-nine patients (4%) had fatal TEAEs, including pneumonia (n = 9), sepsis (n = 4), unspecified cause (n = 4), and multiple organ dysfunction syndrome (n = 5). This analysis demonstrates that zanubrutinib is generally well tolerated with a safety profile consistent with known BTK inhibitor toxicities; these were manageable and mostly reversible.
- Published
- 2022
43. Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry
- Author
-
Anderson, MA, Berkahn, L, Cheah, C, Dickinson, M, Gandhi, MK, Giri, P, Hawkes, EA, Johnston, A, Keane, C, McQuilten, ZK, Mulligan, SP, Opat, S, Talaulikar, D, Trotman, J, Williams, J, Wood, EM, Armytage, T, Barraclough, A, Carradice, D, Chong, G, Cochrane, T, Hamad, N, Ku, M, Lee, D, Morgan, S, Mutsando, H, Narayana, M, Prince, HM, Ratnasingam, S, Wight, J, Badoux, X, Cull, G, Kuss, B, Marlton, P, Tam, C, Casan, J, Cushion, T, Tedjaseputra, A, Birch, S, Brown, C, Ellis, D, Harvey, Y, Hitchins, S, Jain, S, Jessup, P, Juneja, S, Kearney, D, Kumar, B, Lade, S, Lee, K, Leslie, C, Long, E, Morey, A, Nath, L, Norris, D, Parker, A, Parry, J, Chen, FP-Y, Chung, E, Morison, J, Rowsell, L, St George, G, Thu, C, Waters, N, Wellard, C, Zheng, M, Anderson, MA, Berkahn, L, Cheah, C, Dickinson, M, Gandhi, MK, Giri, P, Hawkes, EA, Johnston, A, Keane, C, McQuilten, ZK, Mulligan, SP, Opat, S, Talaulikar, D, Trotman, J, Williams, J, Wood, EM, Armytage, T, Barraclough, A, Carradice, D, Chong, G, Cochrane, T, Hamad, N, Ku, M, Lee, D, Morgan, S, Mutsando, H, Narayana, M, Prince, HM, Ratnasingam, S, Wight, J, Badoux, X, Cull, G, Kuss, B, Marlton, P, Tam, C, Casan, J, Cushion, T, Tedjaseputra, A, Birch, S, Brown, C, Ellis, D, Harvey, Y, Hitchins, S, Jain, S, Jessup, P, Juneja, S, Kearney, D, Kumar, B, Lade, S, Lee, K, Leslie, C, Long, E, Morey, A, Nath, L, Norris, D, Parker, A, Parry, J, Chen, FP-Y, Chung, E, Morison, J, Rowsell, L, St George, G, Thu, C, Waters, N, Wellard, C, and Zheng, M
- Abstract
BACKGROUND: Lymphoma is a malignancy of lymphocytes and lymphoid tissues comprising a heterogeneous group of diseases, with up to 80 entities now described. Lymphoma is the 6th most common cancer in Australia, affecting patients of all ages, with rising incidence rates. With the proliferation of efficacious novel agents, therapeutic strategies are increasingly diverse and survival is improving. There is a clear need for contemporary robust and detailed data on diagnostic, investigational and management strategies for this disease in Australia, New Zealand and worldwide, to inform and benchmark local and international standards of care. Clinical quality registries can provide these data, and support development of strategies to address variations in management, including serving as platforms for clinical trials and other research activities. The Lymphoma and Related Diseases Registry (LaRDR) was developed to capture details of patient demographics, disease characteristics, and management throughout their disease course and therapy and to develop outcome benchmarks nationally and internationally for lymphoma. This report describes the aims, development and implementation of the LaRDR, as well as challenges addressed in the process. METHODS: The LaRDR was established in 2016 as a multicentre, collaborative project at sites across Australia with a secure online database which collects prospective data on patients with a new diagnosis of lymphoma or chronic lymphocytic leukaemia (CLL). LaRDR development required multidisciplinary participation including specialist haematology, information technology, and biostatistical support, as well as secure funding. Here we describe the database development, data entry, ethics approval process, registry governance and support for participating sites and the coordinating centre. RESULTS: To date more than 5,300 patients have been enrolled from 28 sites in Australia and New Zealand. Multiple challenges arose during the development, wh
- Published
- 2022
44. Selective Interstitial Hydration Explains Anomalous Structural Distortions and Ionic Conductivity in 6H-Ba4Ta2O9·1/2H2O.
- Author
-
Marlton, Frederick P., Brown, Alex J., Sale, Matthew, Maljuk, Andrey, Büchner, Bernd, Lewis, William, Luck, Ian, Wood, Michelle L., Mole, Richard A., and Ling, Chris D.
- Published
- 2023
- Full Text
- View/download PDF
45. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
- Author
-
Tam, C.S. Dimopoulos, M. Garcia-Sanz, R. Trotman, J. Opat, S. Roberts, A.W. Owen, R. Song, Y. Xu, W. Zhu, J. Li, J. Qiu, L. D’Sa, S. Jurczak, W. Cull, G. Marlton, P. Gottlieb, D. Munoz, J. Phillips, T. Du, C. Ji, M. Zhou, L. Guo, H. Zhu, H. Chan, W.Y. Cohen, A. Novotny, W. Huang, J. Tedeschi, A.
- Abstract
Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor evaluated in multiple B-cell malignancy studies. We constructed a pooled safety analysis to better understand zanubrutinib-associated treatment-emergent adverse events (TEAEs) and identify treatment-limiting toxicities. Data were pooled from 6 studies (N 5 779). Assessments included type, incidence, severity, and outcome of TEAEs. Median age was 65 years; 20% were $75 years old. Most patients had Waldenstrom € macroglobulinemia (33%), chronic lymphocytic leukemia/small lymphocytic lymphoma (29%), or mantle-cell lymphoma (19%). Median treatment duration was 26 months (range, 0.1-65); 16% of patients were treated for $3 years. Common nonhematologic TEAEs were upper respiratory tract infection (URI, 39%), rash (27%), bruising (25%), musculoskeletal pain (24%), diarrhea (23%), cough (21%), pneumonia (21%), urinary tract infection (UTI), and fatigue (15% each). Most common grade $3 TEAEs were pneumonia (11%), hypertension (5%), URI, UTI, sepsis, diarrhea, and musculoskeletal pain (2% each). Atrial fibrillation and major hemorrhage occurred in 3% and 4% of patients, respectively. Atrial fibrillation, hypertension, and diarrhea occurred at lower rates than those reported historically for ibrutinib. Grade $3 adverse events included neutropenia (23%), thrombocytopenia (8%), and anemia (8%). Serious TEAEs included pneumonia (11%), sepsis (2%), and pyrexia (2%).Treatment discontinuations and dose reductions for adverse events occurred in 10% and 8% of patients, respectively. Thirty-nine patients (4%) had fatal TEAEs, including pneumonia (n 5 9), sepsis (n 5 4), unspecified cause (n 5 4), and multiple organ dysfunction syndrome (n 5 5). This analysis demonstrates that zanubrutinib is generally well tolerated with a safety profile consistent with known BTK inhibitor toxicities; these were manageable and mostly reversible. © 2022 by The American Society of Hematology.
- Published
- 2022
46. RISE-306; State Facilitator Program Evaluation, 1975-1976.
- Author
-
Communication Technology Corp., Marlton, NJ.
- Abstract
As an arm of the National Diffusion Network, the Pennsylvania State Facilitator's responsibilities include informing the schools about Title III approved programs and aiding in the actual adoption of such programs by school districts. Two aspects of the facilitator's role were identified for evaluation: (1) whether the facilitator had implemented the strategy it established to pursue its functions and (2) whether that strategy was successfully meeting the needs of its recipients. Interviews were conducted with a sample of representatives of developer/demonstrator projects and school site adopters. The four national developer/demonstrators interviewed were generally approving of the Pennsylvania Facilitator. They reported the state strategies acceptable in terms of the broader National Diffusion Network (NDN) but recommended changes in the philosophy of the NDN which would expand the responsibilities of the facilitator program. Nine representatives of adopter/adapter districts were interviewed. The concensus of their opinions was positive. The lack of a real grasp of the specific role of the State Facilitator by this group mitigated against an in-depth analysis or specific recommendations for change. (KB)
- Published
- 1976
47. African Free School Evaluation, Regular School Year, and Summer. ESEA Title I, 1970-1971.
- Author
-
Communication Technology Corp., Marlton, NJ.
- Abstract
The African Free School has been in operation as an experimental class, supported by Title I funds since September 1970. The major goals of the program are: (1) to improve the academic and emotional achievement of the students, and (2) to teach racial dignity and pride without teaching racism. The AFS Program consists of the regular AFS experimental class and a control group which was established for purposes of comparative evaluation. Both groups were similar in terms of services received, equipment and supplies available, type of cultural enrichment activities, amount of individual attention, and involvement in the ungraded approach. They differed only in regard to curriculum and instructional methodology. The control group used the regular Newark City School District curriculum, while the experimental AFS group was taught according to the curriculum and methodology of the African Free School which was designed to satisfy the normal requirements for standard subject matter while introducing culturally related materials and curriculum. The academic achievement of the control group appears to be substantially better than that of the AFS Class concerning word knowledge and problem solving. The evaluators feel that the outcomes may be distorted to some degree by the distinctly small sample and the presence of a number of "underachievers" in the AFS class. (Author/JM)
- Published
- 1971
48. Evaluation Report: Newark School District ESEA Title I Program, Summer 1971.
- Author
-
Communication Technology Corp., Marlton, NJ. and Newark Board of Education, NJ.
- Abstract
This evaluation attempts to measure the extent and effectiveness of the 1971 Newark ESEA Title I program that extended the regular school year reading program into the summer months for 19,391 pupils in grades K-12. The instructional activities encompassed remedial and developmental reading, development of language arts skills, and implementation of bilingual programs to improve the skills of both English- and Spanish-speaking children. A wide diversity of outdoor experiential activities that incorporated basic skills learning components were included. Evaluation data were assembled from interview and questionnaire results of a sample of personnel and students, standardized test scores, and onsite observations. (Author/MLF)
- Published
- 1971
49. Newark School District, Part One -- Regular School Year. ESEA Title I Program, 1972-1973 School Year.
- Author
-
Communication Technology Corp., Marlton, NJ. and Newark Board of Education, NJ.
- Abstract
The overall goal of the 1972-73 Title I Program in the Newark School District was to diagnose reading difficulties of and provide preventive, individualized, developmental, and/or remedial programs for children who had demonstrated extreme educational deficiencies. This evaluation attempts to measure the extent and effectiveness of various reading programs implemented during the 1972-73 school year for disadvantaged elementary and secondary students. The document is presented in five color-keyed sections that include Conclusions and Recommendations; Program Description (scope, objectives, and activities); Program Evaluation (methodology and overview of total evaluative process); Evaluation Findings and Discussion; and Appendixes (tabular postings of test score analyses and the reading intervention longitudinal study report.) Also included is a comparative analysis of Title I and non-Title I student achievement during the school year. Results of this analysis reveal that the nearly 14,000 Title I students (K-3) who participated in the program registered progress in reading achievement either beyond or equal to that achieved by their non-Title I peers. (Author/EA)
- Published
- 1973
50. Probing Colossal Carbon Rings.
- Author
-
Marlton, Samuel J.P., Buntine, Jack T., Watkins, Patrick, Liu, Chang, Jacovella, Ugo, Carrascosa, Eduardo, Bull, James N., and Bieske, Evan J.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.